65,437 trials
Psychological Distress · Anxiety · Depression
Primary: Depressive Symptoms — 11.76; 11.55; 11.70; 10.84 score on a scale — p=0.837
Vulvovaginal Candidiasis
Primary: Clinical Cure Rate at Day 7-14 — 10; 16 Participants
Weight Loss
Primary: Body Weight (kg) — 75.2; 79.2; 80.3; 74.5 kg
Colorectal Cancer · Gastric Cancer · Esophageal Cancer
Primary: Unplanned Chemotherapy Treatment Delay — 16 Participants
Healthy
Primary: Decrease in Cinnamaldehyde (CA)-Induced Dermal Blood Flow (DBF) Relative to Placebo Measured by Laser Doppler Imaging (LDI) at 3 Hours Post-dose (LDI) — -9.46; -6.96…
Schizophrenia
Primary: Social Cognitive Measures — 0.11; -1.68 score on a scale
Shellfish Poisoning, Paralytic
Primary: Student Assessment Questionnaire of Student Learning From Each Educational Unit. — 4.2; 3.9 Scores on a scale — p=0.05
Opioid-use Disorder · Mental Health Disorder
Primary: Opioid Use Other Than As Prescribed — 3.92; 0.72 Days — p=<0.001
Schizophrenia
Primary: Change From Baseline to Day 28 in Positive and Negative Syndrome Scale (PANSS) Total Score — -13.2; -8.3; -7.4; -13.4 score on a scale — p=0.017
Advanced Solid Tumors
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Lactation Suppressed
Primary: Number of Participants Reporting Breast Pain — 16; 30 Participants
Ischemic Heart Disease
Primary: The Incidence of Adverse Events - Total Adverse Events (AE) — 58; 18; 36; 0 Total AEs
Cancer
Primary: Number of Domains Considered Relevant by the Panel of Experts When Assessing Treatment Efficacy in Randomized Cancer Trials for Older Patients With Cancer — 7 geriatric…
Non-alcoholic Steatohepatitis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Possibly or Probably Related to Treatment — 0; 0; 1; 3 participants
Wet Age-related Macular Degeneration
Primary: Average Change in Best Corrected Visual Acuity (BCVA) From Baseline Averaged Over Weeks 28 and 32 — 1.17; 1.05; 0.87 score on a scale — p=0.919